Fundamental Analysis of RALLYBIO CORP(NASDAQ:RLYB) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to RLYB. RLYB was compared to 588 industry peers in the Biotechnology industry. While RLYB has a great health rating, there are worries on its profitability. RLYB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RLYB has reported negative net income.

In the past year RLYB has reported a negative cash flow from operations.

RLYB had negative earnings in each of the past 5 years.

In the past 5 years RLYB always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of RLYB (-64.49%) is worse than 61.47% of its industry peers.

Looking at the Return On Equity, with a value of -70.22%, RLYB is in line with its industry, outperforming 56.68% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-64.49%
ROE	-70.22%
ROIC	N/A

ROA(3y)-42.41%

ROA(5y)-45.43%

ROE(3y)-45.45%

ROE(5y)-51.94%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RLYB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, RLYB has about the same amount of shares outstanding.

RLYB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

RLYB has an Altman-Z score of -0.04. This is a bad value and indicates that RLYB is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -0.04, RLYB is in the better half of the industry, outperforming 61.30% of the companies in the same industry.

There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.04

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 12.39 indicates that RLYB has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 12.39, RLYB belongs to the top of the industry, outperforming 85.45% of the companies in the same industry.

RLYB has a Quick Ratio of 12.39. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 12.39, RLYB belongs to the best of the industry, outperforming 85.45% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	12.39
Quick Ratio	12.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.80% over the past year.

EPS 1Y (TTM)12.8%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-8.7%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

RLYB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.44% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y12.9%

EPS Next 2Y9.36%

EPS Next 3Y7.07%

EPS Next 5Y1.44%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RLYB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLYB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.36%

EPS Next 3Y7.07%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RLYB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

RALLYBIO CORP

NASDAQ:RLYB (4/26/2024, 7:13:46 PM)

After market: 1.65 -0.05 (-2.94%)

1.7

+0.05 (+3.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap64.28M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-64.49%
ROE	-70.22%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	12.39
Quick Ratio	12.39
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)12.8%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y12.9%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

RALLYBIO CORP (RLYB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens